A new drug design targeting the adenosinergic system for huntington's disease

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Huang, Nai Kuei ^a   Lin, Jung Hsin ^b,c,d   Lin, Jiun Tsai ^c   Lin, Chia I ^d   Liu, Eric Minwei ^d   Lin, Chun Jung ^d   Chen, Wan Ping ^a   Shen, Yuh Chiang ^a   Chen, Hui Mei ^c   Chen, Jhih Bin ^d   Lai, Hsing Lin ^c   Yang, Chieh Wen ^d   Chiang, Ming Chang ^f   Wu, Yu Shuo ^c   Chang, Chen ^c   Chen, Jiang Fan ^g   Fang, Jim Min ^d,e   Lin, Yun Lian ^a   Chern, Yijuang ^c  

^a NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

^b RESEARCH CENTER FOR APPLIED SCIENCES   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e GENOMICS RESEARCH CENTER   (Taiwan)

^f CHINESE CULTURE UNIVERSITY   (Taiwan)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; N6 (4 HYDROXYBENZYL)ADENINE RIBOSIDE; PROTEIN INHIBITOR; T 1 11; UNCLASSIFIED DRUG; DRUG DERIVATIVE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; HERBACEOUS AGENT; N6-(4-HYDROXYBENZYL)ADENINE RIBOSIDE; PEPTIDE; PLANT EXTRACT; POLYGLUTAMINE; SLC29A1 PROTEIN, MOUSE;

APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG PURIFICATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; MICRODIALYSIS; MOLECULAR MODEL; MOTOR COORDINATION; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN FUNCTION; TREATMENT DURATION; ANIMAL; CELL STRAIN; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; MALE; METABOLISM; MOUSE; MOUSE MUTANT; PATHOPHYSIOLOGY; RAT; TRINUCLEOTIDE REPEAT;

MUS; MUS MUSCULUS;

ADENOSINE; ANIMALS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUGS, CHINESE HERBAL; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, KNOCKOUT; MODELS, MOLECULAR; PC12 CELLS; PEPTIDES; PLANT EXTRACTS; RATS; RECEPTOR, ADENOSINE A2A; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 79959352258     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020934     Document Type: Article

References (94)

1. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983.
2. Chiang MC, Chen HM, Lee YH, Chang HH, Wu YC, et al. (2007) Dysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease. Hum Mol Genet 16: 483-498.
3. Panov AV, Lund S, Greenamyre JT, (2005) Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. Mol Cell Biochem 269: 143-152.
4. Brusa L, Orlacchio A, Moschella V, Iani C, Bernardi G, et al. (2009) Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 24: 126-129.
5. Fredholm BB, Chen JF, Cunha RA, Svenningsson P, Vaugeois JM, (2005) Adenosine and brain function. Int Rev Neurobiol 63: 191-270.
6. Dworak M, Diel P, Voss S, Hollmann W, Struder HK, (2007) Intense exercise increases adenosine concentrations in rat brain: implications for a homeostatic sleep drive. Neurosci 150: 789-795.
7. Lee FS, Chao MV, (2001) Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc Natl Acad Sci U S A 98: 3555-3560.
8. Flajolet M, Wang Z, Futter M, Shen W, Nuangchamnong N, et al. (2008) FGF acts as a co-transmitter through adenosine A2A receptor to regulate synaptic plasticity. Nat Neurosci 11: 1402-1409.
9. Gomes CA, Vaz SH, Ribeiro JA, Sebastiao AM, (2006) Glial cell line-derived neurotrophic factor (GDNF) enhances dopamine release from striatal nerve endings in an adenosine A2A receptor-dependent manner. Brain Res 1113: 129-136.
10. Blum D, Galas MC, Pintor A, Brouillet E, Ledent C, et al. (2003) A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. J Neurosci 23: 5361-5369.
11. Cepeda C, Cummings DM, Hickey MA, Kleiman-Weiner M, Chen JY, et al. (2010) Rescuing the Corticostriatal Synaptic Disconnection in the R6/2 Mouse Model of Huntington's Disease: Exercise, Adenosine Receptors and Ampakines. PLoS Curr 2.
12. Chiang MC, Chen HM, Lai HL, Chen HW, Chou SY, et al. (2009) The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system. Hum Mol Genet 18: 2929-2942.
13. Chou SY, Lee YC, Chen HM, Chiang MC, Lai HL, et al. (2005) CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J Neurochem 93: 310-320.
14. Mievis S, Blum D, Ledent C, (2011) A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease. Neurobiol Dis 41: 570-576.
15. Orru M, Bakesova J, Brugarolas M, Quiroz C, Beaumont V, et al. (2011) Striatal Pre- and Postsynaptic Profile of Adenosine A2A Receptor Antagonists. PloS One 6: e16088.
16. Fink JS, Kalda A, Ryu H, Stack EC, Schwarzschild MA, et al. (2004) Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage. J Neurochem 88: 538-544.
17. Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, et al. (2006) A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet 45: 1201-1212.
18. An SJ, Park SK, Hwang IK, Choi SY, Kim SK, et al. (2003) Gastrodin decreases immunoreactivities of gamma-aminobutyric acid shunt enzymes in the hippocampus of seizure-sensitive gerbils. J Neurosci Res 71: 534-543.
19. Kim HJ, Moon KD, Lee DS, Lee SH, (2003) Ethyl ether fraction of Gastrodia elata Blume protects amyloid beta peptide-induced cell death. J Ethnopharmacol 84: 95-98.
20. Huang NK, Lin YL, Cheng JJ, Lai WL, (2004) Gastrodia elata prevents rat pheochromocytoma cells from serum-deprived apoptosis: the role of the MAPK family. Life Sci 75: 1649-1657.
21. Huang NK, Chern Y, Fang JM, Lin CI, Chen WP, et al. (2007) Neuroprotective principles from Gastrodia elata. J Nat Prod 70: 571-574.
22. Hayashi J, Sekine T, Deguchi S, Lin Q, Horie S, et al. (2002) Phenolic compounds from Gastrodia rhizome and relaxant effects of related compounds on isolated smooth muscle preparation. Phytochem 59: 513-519.
23. Lin JH, Liu YC, Hau JP, Wen KC, (1996) Parishins B and C from rhizomes of Gastrodia elata. Phytochem 42: 549-551.
24. Taguchi H, Yosioka I, Yamasaki K, Kim IH, (1981) Studies on the Constituents of Gastrodia elata Blume. Chem Pharm Bull 29: 55-62.
25. Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, et al. (1999) A2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19: 9192-9200.
26. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EYT, et al. (2008) The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist. Science 322: 1211-1217.
27. Jiang QL, VanRhee AM, Kim JH, Yehle S, Wess J, et al. (1996) Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition. Mol Pharm 50: 512-521.
28. Kim J, Wess J, van Rhee AM, Schoneberg T, Jacobson KA, (1995) Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. J Biol Chem 270: 13987-13997.
29. Kim JH, Jiang QL, Glashofer M, Yehle S, Wess J, et al. (1996) Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. Mol Pharm 49: 683-691.
30. Gao ZG, Jiang QL, Jacobson KA, Ijzerman AP, (2000) Site-directed mutagenesis studies of human A2A adenosine receptors- Involvement of Glu(13) and His(278) in ligand binding and sodium modulation. Biochem Pharm 60: 661-668.
31. Abramson J, Smirnova I, Kasho V, Verner G, Kaback HR, et al. (2003) Structure and mechanism of the lactose permease of Escherichia coli. Science 301: 610-615.
32. Jennings LL, Hao C, Cabrita MA, Vickers MF, Baldwin SA, et al. (2001) Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system. Neuropharmcol 40: 722-731.
33. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, et al. (2001) Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease. Science 293: 493-498.
34. Parkinson FE, Xiong W, Zamzow CR, Chestley T, Mizuno T, et al. (2009) Transgenic expression of human equilibrative nucleoside transporter 1 in mouse neurons. J Neurochem 109: 562-572.
35. Gidday JM, Kim YB, Shah AR, Gonzales ER, Park TS, (1996) Adenosine transport inhibition ameliorates postischemic hypoperfusion in pigs. Brain Res 734: 261-268.
36. Fredholm BB, Fastbom J, Kvanta A, Gerwins P, Parkinson F, (1992) Further evidence that propentofylline (HWA 285) influences both adenosine receptors and adenosine transport. Fundam Clin Pharmacol 6: 99-111.
37. Popoli P, Blum D, Domenici MR, Burnouf S, Chern Y, (2008) A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease. Curr Pharm Des 14: 1500-1511.
38. Tebano MT, Martire A, Chiodi V, Ferrante A, Popoli P, (2010) Role of adenosine A2A receptors in modulating synaptic functions and brain levels of BDNF: a possible key mechanism in the pathophysiology of Huntington's disease. Scientific World Journal 10: 1768-1782.
39. Wiese S, Jablonka S, Holtmann B, Orel N, Rajagopal R, et al. (2007) Adenosine receptor A2A-R contributes to motoneuron survival by transactivating the tyrosine kinase receptor TrkB. Proc Natl Acad Sci U S A 104: 17210-17215.
40. Assaife-Lopes N, Sousa VC, Pereira DB, Ribeiro JA, Chao MV, et al. (2010) Activation of adenosine A2A receptors induces TrkB translocation and increases BDNF-mediated phospho-TrkB localization in lipid rafts: implications for neuromodulation. J Neurosci 30: 8468-8480.
41. Fontinha BM, Diogenes MJ, Ribeiro JA, Sebastiao AM, (2008) Enhancement of long-term potentiation by brain-derived neurotrophic factor requires adenosine A2A receptor activation by endogenous adenosine. Neuropharmacol 54: 924-933.
42. Golder FJ, Ranganathan L, Satriotomo I, Hoffman M, Lovett-Barr MR, et al. (2008) Spinal adenosine A2a receptor activation elicits long-lasting phrenic motor facilitation. J Neurosci 28: 2033-2042.
43. Jin K, LaFevre-Bernt M, Sun Y, Chen S, Gafni J, et al. (2005) FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci U S A 102: 18189-18194.
44. Kells AP, Fong DM, Dragunow M, During MJ, Young D, et al. (2004) AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther 9: 682-688.
45. Chiang MC, Lee YC, Huang CL, Chern Y, (2005) cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. J Biol Chem 280: 14331-14340.
46. Tarditi A, Camurri A, Varani K, Borea PA, Woodman B, et al. (2006) Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. Neurobiol Dis 23: 44-53.
47. Varani K, Abbracchio MP, Cannella M, Cislaghi G, Giallonardo P, et al. (2003) Aberrant A2A receptor function in peripheral blood cells in Huntington's disease. FASEB J 17: 2148-2150.
48. Ribeiro FM, Paquet M, Ferreira LT, Cregan T, Swan P, et al. (2010) Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington's disease. J Neurosci 30: 316-324.
49. Joshi PR, Wu NP, Andre VM, Cummings DM, Cepeda C, et al. (2009) Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci 29: 2414-2427.
50. Martire A, Calamandrei G, Felici F, Scattoni ML, Lastoria G, et al. (2007) Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice. Neurosci Lett 417: 78-83.
51. Domenici MR, Scattoni ML, Martire A, Lastoria G, Potenza RL, et al. (2007) Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Neurobiol Dis 28: 197-205.
52. Dai SS, Zhou YG, Li W, An JH, Li P, et al. (2010) Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury. J Neurosci 30: 5802-5810.
53. He ZX, Cwajg E, Hwang W, Hartley CJ, Funk E, et al. (2000) Myocardial blood flow and myocardial uptake of (201)Tl and (99m)Tc-sestamibi during coronary vasodilation induced by CGS-21680, a selective adenosine A2A receptor agonist. Circulation 102: 438-444.
54. Mingote S, Pereira M, Farrar AM, McLaughlin PJ, Salamone JD, (2008) Systemic administration of the adenosine A2A agonist CGS 21680 induces sedation at doses that suppress lever pressing and food intake. Pharmacol Biochem Behav 89: 345-351.
55. Jacobson KA, Park KS, Jiang JL, Kim YC, Olah ME, et al. (1997) Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacol 36: 1157-1165.
56. Blum D, Gall D, Galas MC, d'Alcantara P, Bantubungi K, et al. (2002) The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J Neurosci 22: 9122-9133.
57. Luo C, Yi B, Tao G, Li M, Chen Z, et al. (2010) Adenosine A3 receptor agonist reduces early brain injury in subarachnoid haemorrhage. Neuroreport 21: 892-896.
58. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C, (2009) Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst Rev pp. CD006455.
59. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, et al. (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5: 749-757.
60. Tzschentke TM, Christoph T, Koegel B, Schiene K, Hennies HH, et al. (2007) (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)- phenol hydrochloride (Tapentadol HCl): a novel mu-opioid receptor agonist norepinephrine Reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 323: 265-276.
61. Chen JF, Steyn S, Staal R, Petzer JP, Xu K, et al. (2002) 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. J Biol Chem 277: 36040-36044.
62. Rooseboom M, Commandeur JN, Vermeulen NP, (2004) Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 56: 53-102.
63. Too K, Brown DM, Bongard E, Yardley V, Vivas L, et al. (2007) Anti-malarial activity of N6-modified purine analogues. Bioorg Med Chem 15: 5551-5562.
64. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
65. Huang NK, Lin YW, Huang CL, Messing RO, Chern Y, (2001) Activation of protein kinase A and atypical protein kinase C by A2A adenosine receptors antagonizes apoptosis due to serum deprivation in PC12 cells. J Biol Chem 276: 13838-13846.
66. Huang NK, Cheng JJ, Lai WL, Lu MK, (2005) Antrodia camphorata prevents rat pheochromocytoma cells from serum deprivation-induced apoptosis. FEMS Microbiol Lett 244: 213-219.
67. Varani K, Gessi S, Dalpiaz A, Borea PA, (1996) Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]-CGS 21680 binding. Br J Pharmacol 117: 1693-1701.
68. Olah ME, Gallo-Rodriguez C, Jacobson KA, Stiles GL, (1994) 125I-4-aminobenzyl-5′-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor. Mol Pharmacol 45: 978-982.
69. Salvatore CA, Jacobson MA, Taylor HE, Linden J, Johnson RG, (1993) Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci U S A 90: 10365-10369.
70. Verma A, Marangos PJ, (1985) Nitrobenzylthioinosine binding in brain: an interspecies study. Life Sci 36: 283-290.
71. Ward JL, Sherali A, Mo ZP, Tse CM, (2000) Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. Ent2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J Biol Chem 275: 8375-8381.
72. Huang NK, Tseng CJ, Wong CS, Tung CS, (1997) Effects of acute and chronic morphine on DOPAC and glutamate at subcortical DA terminals in awake rats. Pharmacol Biochem Behav 56: 363-371.
73. Lu MK, Cheng JJ, Lai WL, Lin YR, Huang NK, (2006) Adenosine as an active component of Antrodia cinnamomea that prevents rat PC12 cells from serum deprivation-induced apoptosis through the activation of adenosine A(2A) receptors. Life Sci 79: 252-258.
74. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506.
75. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, et al. (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19: 3248-3257.
76. Sathasivam K, Hobbs C, Turmaine M, Mangiarini L, Mahal A, et al. (1999) Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 8: 813-822.
77. Liu FC, Wu GC, Hsieh ST, Lai HL, Wang HF, et al. (1998) Expression of type VI adenylyl cyclase in the central nervous system: implication for a potential regulator of multiple signals in different neurotransmitter systems. FEBS Lett 436: 92-98.
78. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
79. Thompson JD, Higgins DG, Gibson TJ, (1994) Clustal-W- Improving the Sensitivity of Progressive Multiple Sequence Alignment through Sequence Weighting, Position-Specific Gap Penalties and Weight Matrix Choice. Nucl Acids Res 22: 4673-4680.
80. Boeckmann B, Bairoch A, Apweiler R, Blatter MC, Estreicher A, et al. (2003) The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucl Acids Res 31: 365-370.
81. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, et al. (2008) Crystal structure of opsin in its G-protein-interacting conformation. Nature 455: 497-U430.
82. Xiang ZX, Soto CS, Honig B, (2002) Evaluating conformational free energies: The colony energy and its application to the problem of loop prediction. Proc Natl Acad Sci U S A 99: 7432-7437.
83. Sali A, Blundell TL, (1993) Comparative Protein Modeling by Satisfaction of Spatial Restraints. J Mol Biol 234: 779-815.
84. Shen MY, Sali A, (2006) Statistical potential for assessment and prediction of protein structures. Prot Sci 15: 2507-2524.
85. Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, et al. (2007) PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucl Acids Res 35: W522-W525.
86. Xu F, Wu H, Katritch V, Han GW, Jacobson KA, et al. (2011) Structure of an agonist-bound human A2A adenosine receptor. Science 332: 322-327.
87. Zhang Y, (2008) I-TASSER server for protein 3D structure prediction. Bmc Bioinformatics 9.
88. Zhang Y, Skolnick J, (2004) Automated structure prediction of weakly homologous proteins on a genomic scale'. Proc Natl Acad Sci U S A 101: 7594-7599.
89. Lin JH, Baker NA, McCammon JA, (2002) Bridging implicit and explicit solvent approaches for membrane electrostatics. Biophys J 83: 1374-1379.
90. Wu XW, Brooks BR, (2003) Self-guided Langevin dynamics simulation method. Chem Phys Lett 381: 512-518.
91. Simmerling C, Strockbine B, Roitberg AE, (2002) All-atom structure prediction and folding simulations of a stable protein. J Am Chem Soc 124: 11258-11259.
92. Case DA, Darden TA, Cheatham ITE, Simmerling CL, Wang RE, et al. (2006) AMBER 9. University of California, San Diego.
93. Gasteiger J, Marsili M, (1980) Iterative Partial Equalization of Orbital Electronegativity- a Rapid Access to Atomic Charges. Tetrahedron 36: 3219-3228.
94. Huey R, Morris GM, Olson AJ, Goodsell DS, (2007) A semiempirical free energy force field with charge-based desolvation. Journal of Computational Chemistry 28: 1145-1152.